Literature DB >> 24827773

Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients.

C Wintenberger1, I Boccon-Gibod, D Launay, O Fain, G Kanny, P Y Jeandel, L Martin, A Gompel, L Bouillet.   

Abstract

Angioedema (AE) is a clinical syndrome characterized by localised swelling lasting several hours. The swelling is often recurring and can be lethal if it is located in the laryngeal region. Much progress has been made recently in the treatment of acute episodes, but no consensus has been reached on maintenance treatment. We have performed a national retrospective observational study to assess the use of tranexamic acid (TA) as maintenance treatment for non-histaminergic AE [hereditary AE (HAE) or idiopathic non-histaminergic AE]. Records for 64 cases were collected from 1 October 2012 to 31 August 2013; 37 of these were included (12 HAE with C1-inhibitor deficiency, six with HAE with normal C1-inhibitor and 19 idiopathic non-histaminergic AE). When treated with TA over six months, the number of attacks was reduced by 75% in 17 patients, 10 patients showed a lower level of reduction and 10 had the same number of attacks. In no instances were symptoms increased. No thromboembolic events were observed, and the main side effects were digestive in nature. Thus, TA, which is well tolerated and inexpensive, appears to be an effective maintenance treatment for some patients with HAE or idiopathic non-histaminergic AE.
© 2014 British Society for Immunology.

Entities:  

Keywords:  angioedema; bradykinin; hereditary angioedema; tranexamic acid

Mesh:

Substances:

Year:  2014        PMID: 24827773      PMCID: PMC4360201          DOI: 10.1111/cei.12379

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group.

Authors:  M Cicardi; K Bork; T Caballero; T Craig; H H Li; H Longhurst; A Reshef; B Zuraw
Journal:  Allergy       Date:  2011-11-30       Impact factor: 13.146

2.  Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema.

Authors:  A Du-Thanh; N Raison-Peyron; C Drouet; B Guillot
Journal:  Allergy       Date:  2009-11-03       Impact factor: 13.146

3.  Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study.

Authors:  G Blohmé
Journal:  Acta Med Scand       Date:  1972-10

4.  Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study.

Authors:  M M Frank; J S Sergent; M A Kane; D W Alling
Journal:  N Engl J Med       Date:  1972-04-13       Impact factor: 91.245

Review 5.  [Hereditary angioedema: a therapeutic revolution].

Authors:  L Bouillet
Journal:  Rev Med Interne       Date:  2012-01-09       Impact factor: 0.728

6.  Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid.

Authors:  M Cugno; M Cicardi; A Agostoni
Journal:  J Allergy Clin Immunol       Date:  1994-05       Impact factor: 10.793

7.  Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel.

Authors:  Bruce L Zuraw; Konrad Bork; Karen E Binkley; Aleena Banerji; Sandra C Christiansen; Anthony Castaldo; Allen Kaplan; Marc Riedl; Charles Kirkpatrick; Markus Magerl; Christian Drouet; Marco Cicardi
Journal:  Allergy Asthma Proc       Date:  2012 Nov-Dec       Impact factor: 2.587

Review 8.  The spectrum and treatment of angioedema.

Authors:  Viviana M Temiño; R Stokes Peebles
Journal:  Am J Med       Date:  2008-04       Impact factor: 4.965

9.  Benefits of progestin contraception in non-allergic angioedema.

Authors:  C Saule; I Boccon-Gibod; O Fain; G Kanny; G Plu-Bureau; L Martin; D Launay; L Bouillet; A Gompel
Journal:  Clin Exp Allergy       Date:  2013-04       Impact factor: 5.018

10.  Long-term prophylaxis in hereditary angio-oedema: a systematic review.

Authors:  Giorgio Costantino; Giovanni Casazza; Ilaria Bossi; Piergiorgio Duca; Marco Cicardi
Journal:  BMJ Open       Date:  2012-07-11       Impact factor: 2.692

View more
  15 in total

Review 1.  Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients.

Authors:  Charles Faisant; Aurélie Du Thanh; Catherine Mansard; Alban Deroux; Isabelle Boccon-Gibod; Laurence Bouillet
Journal:  J Clin Immunol       Date:  2016-11-08       Impact factor: 8.317

Review 2.  An Update on the Use of Immunomodulators in Primary Immunodeficiencies.

Authors:  Pandiarajan Vignesh; Amit Rawat; Surjit Singh
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

Review 3.  Differential Diagnosis and Management Issues of Idiopathic Angiooedema and their Resolution.

Authors:  Andrea Zanichelli; Marta Mansi; Maddalena A Wu; Giulia Azin; Marco Cicardi
Journal:  J Crit Care Med (Targu Mures)       Date:  2015-06-05

Review 4.  Clinical manifestations of hereditary angioedema and a systematic review of treatment options.

Authors:  Mattie Rosi-Schumacher; Sejal J Shah; Timothy Craig; Neerav Goyal
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-04-03

5.  An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.

Authors:  Marc A Riedl; Jonathan A Bernstein; Timothy Craig; Aleena Banerji; Markus Magerl; Marco Cicardi; Hilary J Longhurst; Mustafa M Shennak; William H Yang; Jennifer Schranz; Jovanna Baptista; Paula J Busse
Journal:  Clin Transl Allergy       Date:  2017-10-06       Impact factor: 5.871

6.  Hereditary angioedema with C1 inhibitor (C1-INH) deficit: the strength of recognition (51 cases).

Authors:  N T M L Fragnan; A L N Tolentino; G B Borba; A C Oliveira; J A Simões; S M U Palma; R N Constantino-Silva; A S Grumach
Journal:  Braz J Med Biol Res       Date:  2018-11-14       Impact factor: 2.590

7.  Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes.

Authors:  Masayuki Takeyama; Fumio Takeuchi; Masahiko Gosho; Keijiro Sugita; Masahiro Zako; Masayoshi Iwaki; Motohiro Kamei
Journal:  Clin Ophthalmol       Date:  2017-12-20

8.  Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials.

Authors:  Martin Christian Bucher; Tatjana Petkovic; Arthur Helbling; Urs Christian Steiner
Journal:  Clin Transl Allergy       Date:  2017-08-31       Impact factor: 5.871

Review 9.  Efficacy of Treatment of Non-hereditary Angioedema.

Authors:  Mignon van den Elzen; M F C L Go; A C Knulst; M A Blankestijn; H van Os-Medendorp; H G Otten
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

10.  Omalizumab for Idiopathic Nonhistaminergic Angioedema: Evidence for Efficacy in 2 Patients.

Authors:  Enrico Brunetta; Dana Shiffer; Marco Folci; Maria I S Achenza; Francesca Puggioni; Enrico Heffler; Raffaello Furlan; Giorgio W Canonica
Journal:  Case Reports Immunol       Date:  2018-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.